Atea Pharma’s Phase 2 Study Of Bemnifosbuvir, Ruzasvir In HCV Achieves Primary Endpoint, Stock Up
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Atea Pharmaceuticals, Inc. (AVIR) Wednesday revealed that its Phase 2 study of Bemnifosbuvir and Ruzasvir Regimen for the treatment of Hepatitis C Virus or HCV achieved primary endpoint of safety and sustained virologic response.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1276355499-1190b5c71e7645e4907a72fc4d17ce81.jpg "7 Affordable ETFs for Your Portfolio in 2025")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2165653808-a6ede2df4d014be98ddd01aa05516d22.jpg "How Long Will It Take to Double Your Money? This Formula Shows You")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1089667012-98b2eb511cee47a18dadbee0d1fc95cf.jpg)
" title=":max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1190440276-7d155cce64c943079a4d50be199fed9c.jpg "What Does Amortization Mean in the Context of a Pension Plan?")
:max_bytes(150000):strip_icc():format(jpeg)/Hostile-Takeover-Final-18284f0c8dca4b4696feca038afcb61f.jpg "How Can a Company Resist a Hostile Takeover?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1944599261-5b582e3bb90c49fa837e054b0328bc67.jpg "The Best Way to Give the Gift of Travel")
